These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34177879)

  • 21. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.
    González-Stegmaier R; Cereceda K; Briones JL; Beltran-Pávez C; Oyarzún-Arrau A; Riquelme-Barrios S; Selman C; Yarad F; Mahave M; Caglevic C; Morales R; Aguirre A; Valiente-Echeverría F; Soto-Rifo R; Marsiglia H; Gazitua R; Villarroel-Espindola F
    J Immunol Res; 2021; 2021():6680337. PubMed ID: 33644235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
    Demers-Mathieu V; DaPra C; Medo E
    Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
    [No Abstract]   [Full Text] [Related]  

  • 24. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
    Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
    J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
    Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
    Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.
    Ramos I; Goforth C; Soares-Schanoski A; Weir DL; Samuels EC; Phogat S; Meyer M; Huang K; Pietzsch CA; Ge Y; Pike BL; Regeimbal J; Simons MP; Termini MS; Vangeti S; Marjanovic N; Lizewski S; Lizewski R; George MC; Nair VD; Smith GR; Mao W; Chikina M; Broder CC; Laing ED; Bukreyev A; Sealfon SC; Letizia AG
    Front Immunol; 2021; 12():681586. PubMed ID: 34177926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
    Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X
    Front Immunol; 2021; 12():708523. PubMed ID: 34220870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease.
    Brynjolfsson SF; Sigurgrimsdottir H; Einarsdottir ED; Bjornsdottir GA; Armannsdottir B; Baldvinsdottir GE; Bjarnason A; Gudlaugsson O; Gudmundsson S; Sigurdardottir ST; Love A; Kristinsson KG; Ludviksson BR
    Front Immunol; 2021; 12():695230. PubMed ID: 34177962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
    Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
    J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
    Isho B; Abe KT; Zuo M; Jamal AJ; Rathod B; Wang JH; Li Z; Chao G; Rojas OL; Bang YM; Pu A; Christie-Holmes N; Gervais C; Ceccarelli D; Samavarchi-Tehrani P; Guvenc F; Budylowski P; Li A; Paterson A; Yue FY; Marin LM; Caldwell L; Wrana JL; Colwill K; Sicheri F; Mubareka S; Gray-Owen SD; Drews SJ; Siqueira WL; Barrios-Rodiles M; Ostrowski M; Rini JM; Durocher Y; McGeer AJ; Gommerman JL; Gingras AC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
    Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.
    Siracusano G; Brombin C; Pastori C; Cugnata F; Noviello M; Tassi E; Princi D; Cantoni D; Malnati MS; Maugeri N; Bozzi C; Saretto G; Clementi N; Mancini N; Uberti-Foppa C; Temperton N; Bonini C; Di Serio C; Lopalco L
    Front Immunol; 2021; 12():772239. PubMed ID: 34804064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
    Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
    J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan.
    Nagura-Ikeda M; Imai K; Kubota K; Noguchi S; Kitagawa Y; Matsuoka M; Tabata S; Miyoshi K; Ito T; Tamura K; Maeda T
    J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33861191
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.